The Biology of GLP-1
Glucagon-like peptide-1 (GLP-1) is an incretin hormone naturally produced by L-cells in the small intestine in response to food intake. It plays a pivotal role in glucose homeostasis by stimulating insulin secretion from pancreatic beta cells in a glucose-dependent manner, meaning it only enhances insulin release when blood sugar levels are elevated. This mechanism significantly reduces the risk of hypoglycaemia compared to older diabetes medications.
Beyond its effects on insulin, GLP-1 suppresses glucagon secretion from alpha cells, slows gastric emptying, and acts on the hypothalamus to promote satiety. These combined actions make GLP-1 receptor agonists (GLP-1 RAs) remarkably effective for both glycaemic control and weight management — two of the most pressing challenges in modern metabolic medicine.
How GLP-1 Receptor Agonists Work
Synthetic GLP-1 receptor agonists, such as semaglutide and liraglutide, are engineered to resist degradation by the enzyme dipeptidyl peptidase-4 (DPP-4), which normally breaks down native GLP-1 within minutes. This modification extends their half-life from roughly two minutes to days or even a week, allowing for convenient once-weekly dosing in many formulations.
Once administered, these peptides bind to GLP-1 receptors distributed across multiple organ systems — the pancreas, brain, heart, and gastrointestinal tract. Clinical trials such as STEP and SUSTAIN have demonstrated that GLP-1 RAs can produce average weight loss of 15–20% of body weight while simultaneously improving cardiovascular risk markers including blood pressure, lipid profiles, and inflammatory biomarkers.
Clinical Applications in South Africa
In South Africa, access to GLP-1 receptor agonists has historically been limited by cost and availability. Compounded formulations prepared by SAHPRA-compliant pharmacies offer a regulated alternative, ensuring patients receive precise dosing under medical supervision. At DOSIST, our GLP-1 protocols are prescribed by licensed practitioners and dispensed with full pharmaceutical oversight, bridging the gap between cutting-edge metabolic science and accessible patient care.
- Glucose-dependent insulin secretion reduces hypoglycaemia risk
- Appetite suppression via hypothalamic GLP-1 receptor activation
- Cardiovascular benefits demonstrated in landmark clinical trials
- Once-weekly dosing improves patient adherence and outcomes
